» Articles » PMID: 17363497

Bortezomib, but Not Cisplatin, Induces Mitochondria-dependent Apoptosis Accompanied by Up-regulation of Noxa in the Non-small Cell Lung Cancer Cell Line NCI-H460

Overview
Journal Mol Cancer Ther
Date 2007 Mar 17
PMID 17363497
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Defects in the apoptotic machinery may contribute to chemoresistance of non-small cell lung cancer (NSCLC) cells. We have previously showed a deficiency in mitochondria-dependent caspase-9 activation in NSCLC H460 cells after exposure to cisplatin, a drug widely used to treat NSCLC. Here we show that, unlike cisplatin, the novel anticancer agent bortezomib efficiently induces caspase-9 activation and apoptosis in H460 cells. A comparative analysis of molecular events underlying cell death in bortezomib-treated versus cisplatin-treated H460 cells revealed that bortezomib, but not cisplatin, caused a rapid and abundant release of cytochrome c and Smac/DIABLO from mitochondria. This was associated with a marked increase in levels of the BH3-only proapoptotic protein Noxa and the antiapoptotic protein Mcl-1. Taken together, our data show that bortezomib, by promoting a proapoptotic shift in the levels of proteins involved in mitochondrial outer-membrane permeabilization, is a potent activator of the mitochondrial pathway of apoptosis in NSCLC cells. Our preclinical results support further investigation of bortezomib-based therapies as a possible new treatment modality for NSCLC.

Citing Articles

Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB.

Li Y, Xu W, Ren Y, Cheung H, Huang P, Kaur G mBio. 2022; 13(5):e0184922.

PMID: 36043787 PMC: 9600731. DOI: 10.1128/mbio.01849-22.


The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells.

Lee Y, Heo W, Nam J, Jeung Y, Bae J J Radiat Res. 2018; 59(3):245-252.

PMID: 29518205 PMC: 5967576. DOI: 10.1093/jrr/rry005.


Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia.

Du X, Tong J, Lu H, He C, Du S, Jia P Mol Med Rep. 2017; 16(1):101-108.

PMID: 28487980 PMC: 5482122. DOI: 10.3892/mmr.2017.6554.


Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines.

Nguyen A, Hollenbach P, Richard N, Luna-Moran A, Brady H, Heise C Lung Cancer (Auckl). 2017; 1:119-140.

PMID: 28210112 PMC: 5312472. DOI: 10.2147/LCTT.S11726.


Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.

Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S J Cell Mol Med. 2014; 18(6):947-61.

PMID: 24712303 PMC: 4508135. DOI: 10.1111/jcmm.12279.